Navigation Links
At Three Months Post Launch, Two-Thirds of Surveyed U.S. Rheumatologists Believe that Initiations of Pfizer's Xeljanz in the Rheumatoid Arthritis Treatment Algorithm Will Occur Following at Least Two Biologic Failures
Date:4/24/2013

EXTON, Pa., April 24 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that two-thirds of surveyed U.S. rheumatologists believe that—at three months post launch—initiations of Pfizer's Xeljanz in the rheumatoid arthritis (RA) treatment algorithm will follow methotrexate failure/intolerance and at least two biologic failures. Only one in ten surveyed physicians currently plan to use the treatment prior to biologic initiation.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36805LOGO )

According to the BioTrends Research Group report entitled LaunchTrends®: Xeljanz, Wave 2, surveyed rheumatologists report that among their patients currently treated with Xeljanz, 87 percent were switched from a biologic agent, while the remaining 13 percent of current Xeljanz patients were biologic naive prior to initiation. When questioned directly about agents at risk for displacement, nearly one-quarter of rheumatologists believe that Xeljanz is most likely to displace Genentech's Actemra with regard to RA patient share.

The recently published report also reveals that at three months post launch, approximately one-third of surveyed rheumatologists report prescribing Xeljanz in an average of three RA patients. Although rheumatologists anticipate Xeljanz trial rates to increase in the future, four percent claim that they will never use Xeljanz, primarily due to efficacy concerns and side effects.

"The percent of rheumatologists who have used Xeljanz in at least one patient has remained around one-third since the first wave of research, at one-month post launch," said BioTrends Research Group Associate Director of Immunology Lynn Price . "However, according to the data, Xeljanz trial rates are anticipated to double in the coming months."

LaunchTrends®: Xeljanz, Wave 2 is a four-wave syndicated report series designed to track the uptake of Xeljanz at one month, three months, six months and one year following its commercial availability based upon primary research with U.S. rheumatologists. LaunchTrends assess trial and use of new products, obstacles to use, reasons to use, typical patient types, line of therapy, product perceptions, promotional efforts/messages and product satisfaction. In the current wave of research, BioTrends surveyed 74 U.S. rheumatologists in February 2013 and conducted qualitative interviews with a subset of 15 of the respondents in March 2013.

About BioTrends Research Group
BioTrends Research Group provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please contact us at www.bio-trends.com. BioTrends is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort
781-993-2597
ccomfort@dresources.com

 


'/>"/>
SOURCE BioTrends Research Group
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. deCODE Genetics, in Collaboration with Academic Colleagues, Discovers Three Variants in the Sequence of the Human Genome that Affect the Risk of Thyroid Cancer
2. Aviir Laboratories Announce National Agreement with Three Rivers Provider Network
3. Origin Agritech Limited Reports Unaudited Third Quarter Financial Results For Three Months Ended June 30, 2012
4. Seahorse Bioscience Ranks No. 1600 on the Inc. 500
5. 5000 List of Fastest-Growing Private Companies in America for 2012 with Three-Year Sales Growth of 183%
6. Three Hertz Foundation Fellows Receive Presidential Honors; Leaders in Applied Physical, Biological and Engineering Sciences
7. RiboMed Receives Three Additional Patents for Disease Diagnostics Methods
8. RiboMed Receives Three Additional Patents for Disease Diagnostics Methods
9. Alpha Source, Inc. Makes Third Straight Inc. 5000 List with Three-Year Sales Growth of 53%
10. Three Blockbuster Patent Cases at the Supreme Court This Term
11. Origin Agritech Limited Reports Unaudited First Quarter Financial Results For Three Months Ended December 31, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... June 24, 2016  Regular discussions on a range of ... between the two entities said Poloz. Speaking at ... Ottawa , he pointed to the country,s inflation target, ... government. "In certain ... institutions have common economic goals, why not sit down and ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... pleased to announce the launch of their brand, UP4™ Probiotics, into Target stores ... 35 years, is proud to add Target to its list of well-respected retailers. ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... Plate® YM (Yeast and Mold) microbial test has received AOAC Research Institute approval ... of microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory ...
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the ... at the Arkansas State Crime Laboratory, has joined STACS DNA as a Field Application ... team,” said Jocelyn Tremblay, President and COO of STACS DNA. “In further expanding our ...
Breaking Biology Technology:
(Date:4/19/2016)... , UAE, April 20, 2016 ... be implemented as a compact web-based "all-in-one" system solution ... the biometric fingerprint reader or the door interface with ... of modern access control systems. The minimal dimensions of ... ID readers into the building installations offer considerable freedom ...
(Date:4/15/2016)... 15, 2016 Research and ... Biometrics Market 2016-2020,"  report to their offering.  , ... , ,The global gait biometrics market is expected ... the period 2016-2020. Gait analysis generates ... be used to compute factors that are not ...
(Date:4/13/2016)... 2016  IMPOWER physicians supporting Medicaid patients in ... clinical standard in telehealth thanks to a new partnership ... platform, IMPOWER patients can routinely track key health measurements, ... index, and, when they opt in, share them with ... a local retail location at no cost. By leveraging ...
Breaking Biology News(10 mins):